[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100374756":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":17,"centralContacts":21,"locations":7,"responsibleParty":27,"collaborators":7,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":33,"acronym":7,"eligibilityCriteria":34,"healthyVolunteers":31,"sex":35,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":36,"phases":7,"briefSummary":37,"conditions":38,"keywords":53,"overallStatus":60,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":65,"locationsCount":7},{"fullName":5,"class":6},"AbbVie","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Upadacitinib","Upadacitinib will be administered as oral solution.",[14,15,16],"ABT-494","Rinvoq","C25-267",[18],{"name":19,"affiliation":5,"role":20},"ABBVIE INC.","STUDY_DIRECTOR",[22],{"name":23,"role":24,"phone":25,"phoneExt":7,"email":26},"ABBVIE CALL CENTER","CONTACT","844-663-3742","abbvieclinicaltrials@abbvie.com",{"type":28,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100374756","expanded-access-to-upadacitinib-100374756",false,"NCT04159597","Expanded Access to Upadacitinib","Exclusion Criteria:\n\n* There are other suitable treatment options.\n* The participant qualifies for ongoing clinical trials.","ALL","EXPANDED_ACCESS","This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.",[39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Crohn Disease","Ulcerative Colitis","Idiopathic Arthritis (Including sJIA, pJIA, or JPsA)","Atopic Dermatitis","Rheumatoid Arthritis","Psoriatic Arthritis","Axial Spondyloarthritis","Non-radiographic Axial","Spondyloarthritis","Giant Cell Arteritis","Systemic Lupus Erythematosus","Alopecia Areata","Non Segmental Vitiligo","Hidradenitis Suppurativa",[54,55,56,57,58,59],"Expanded Access","Pre-approval Access","Compassionate Use","Special Access Program","Named Patient Basis","Special Access Scheme","AVAILABLE","2026-08-18",{"date":63,"type":64},"2026-08-20","ACTUAL",{"name":5,"class":6}]